- Home
- AKAM vs INCY Comparison
AKAM vs INCY Comparison
Compare AKAM & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKAM
- INCY
- Stock Information
- Founded
- AKAM 1998
- INCY 1991
- Country
- AKAM United States
- INCY United States
- Employees
- AKAM N/A
- INCY N/A
- Industry
- AKAM Business Services
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- AKAM Consumer Discretionary
- INCY Health Care
- Exchange
- AKAM Nasdaq
- INCY Nasdaq
- Market Cap
- AKAM 12.2B
- INCY 13.4B
- IPO Year
- AKAM 1999
- INCY 1993
- Fundamental
- Price
- AKAM $78.38
- INCY $68.46
- Analyst Decision
- AKAM Buy
- INCY Hold
- Analyst Count
- AKAM 22
- INCY 20
- Target Price
- AKAM $105.15
- INCY $73.81
- AVG Volume (30 Days)
- AKAM 2.3M
- INCY 2.0M
- Earning Date
- AKAM 08-07-2025
- INCY 07-29-2025
- Dividend Yield
- AKAM N/A
- INCY N/A
- EPS Growth
- AKAM N/A
- INCY N/A
- EPS
- AKAM 2.97
- INCY 0.10
- Revenue
- AKAM $4,019,337,000.00
- INCY $4,413,226,000.00
- Revenue This Year
- AKAM $5.61
- INCY $13.29
- Revenue Next Year
- AKAM $5.41
- INCY $10.47
- P/E Ratio
- AKAM $26.20
- INCY $705.59
- Revenue Growth
- AKAM 3.51
- INCY 17.13
- 52 Week Low
- AKAM $67.51
- INCY $53.56
- 52 Week High
- AKAM $106.80
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- AKAM 51.57
- INCY 56.95
- Support Level
- AKAM $76.86
- INCY $67.57
- Resistance Level
- AKAM $80.03
- INCY $71.29
- Average True Range (ATR)
- AKAM 1.55
- INCY 1.98
- MACD
- AKAM 0.24
- INCY -0.13
- Stochastic Oscillator
- AKAM 69.10
- INCY 61.55
About AKAM Akamai Technologies Inc.
Akamai operates a content delivery network, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,100 points of presence in more than 1,000 cities worldwide. The firm also offers security and cloud computing for its customers, and those businesses have grown to be bigger than the legacy CDN.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.